Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
As of close of business last night, Trevi Therapeutics Inc’s stock clocked out at $10.62, up 4.22% from its previous closing price of $10.19. In other words, the price has increased by $4.22 from its previous closing price. On the day, 2.18 million shares were traded. TRVI stock price reached its highest trading level at $10.8599 during the session, while it also had its lowest trading level at $10.2511.
Ratios:
To gain a deeper understanding of TRVI’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.42 and its Current Ratio is at 22.42. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on August 21, 2025, initiated with a Overweight rating and assigned the stock a target price of $18.
On July 01, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
On May 28, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $21.H.C. Wainwright initiated its Buy rating on May 28, 2025, with a $21 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 07 ’25 when Delfini Lisa bought 108,650 shares for $9.50 per share.
Delfini Lisa bought 40,000 shares of TRVI for $386,716 on Oct 03 ’25. On Aug 27 ’25, another insider, Delfini Lisa, who serves as the Officer of the company, bought 312,855 shares for $8.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 1293270144 and an Enterprise Value of 1090276224.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.66, which has changed by 2.2660255 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $10.31, while it has fallen to a 52-week low of $2.36. The 50-Day Moving Average of the stock is 27.65%, while the 200-Day Moving Average is calculated to be 66.86%.
Shares Statistics:
It appears that TRVI traded 2.21M shares on average per day over the past three months and 1675890 shares per day over the past ten days. A total of 121.78M shares are outstanding, with a floating share count of 80.73M. Insiders hold about 33.70% of the company’s shares, while institutions hold 61.18% stake in the company. Shares short for TRVI as of 1759190400 were 14825735 with a Short Ratio of 6.70, compared to 1756425600 on 11684736. Therefore, it implies a Short% of Shares Outstanding of 14825735 and a Short% of Float of 14.109999.
Earnings Estimates
Its stock is currently analyzed by 8.0 different market analysts. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.1 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.38 and -$0.44 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.49, with 8.0 analysts recommending between -$0.24 and -$0.65.
